Journal: JAMA Oncology

Article Title: Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

doi: 10.1001/jamaoncol.2022.5370

Figure Lengend Snippet: A, Kaplan-Meier plot comparing overall survival for patients with newly diagnosed glioblastoma treated with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) and 1366 contemporaneous matched external control participants (ECPs) treated with standard of care, derived from 5 other contemporaneous matched randomized clinical trials. B, Cox hazard ratios of overall survival in prespecified subgroups of participants receiving DCVax-L or treated with standard of care in external trials. In the age subgroup, there were 50 participants in the DCVax-L group and 45 in the ECP group aged 65 years or greater and 182 and 184, respectively in the younger than 65 years group; in the residual disease subgroup, there were 86 patients in the DCVax-L group and 163 in the ECP group with significant residual disease and 146 and 210, respectively, with minimal residual disease; in the MGMT (O 6 -methylguanine-DNA methyltransferase) subgroup, there were 90 patients in the DCVax-L group and 199 in the ECP group with methylated MGMT and 131 and 349, respectively, with unmethylated MGMT. Subgroup analyses of survival, using the same parameters as the comparator publications, are presented with 95% confidence intervals to facilitate comparisons with the ECP.

Article Snippet: The MGMT (O 6 -methylguanine-DNA methyltransferase) gene promoter methylation status, IDH (isocitrate dehydrogenase) R132 mutation status, and postsurgery minimal (<2 cm 2 ) vs significant (≥2 cm 2 ) residual tumor were determined centrally (LabCorp; Mayo; ICON).

Techniques: Control, Derivative Assay, Clinical Proteomics, Methylation

Journal: Acta Neuropathologica Communications

Article Title: Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3 - TACC3 fusions

doi: 10.1186/s40478-020-01058-6

Figure Lengend Snippet: Kaplan-Meier analysis of overall survival stratified by FGFR3 - TACC3 fusion ( a ) and MGMT promoter hypermethylation ( b ) status. Note : Overall survival was defined as the time from initial diagnostic biopsy until the time of death due to any cause. Two-sided p values for difference were calculated using the log-rank test

Article Snippet: Reported MGMT promoter hypermethylation status, typically determined by pyrosequencing, was extracted from the electronic medical record for those patients who did not undergo methylation analysis on the Infinium platform [ ].

Techniques: Diagnostic Assay

Journal: Cancer Imaging

Article Title: Assessment of MGMT promoter methylation status in glioblastoma using deep learning features from multi-sequence MRI of intratumoral and peritumoral regions

doi: 10.1186/s40644-024-00817-1

Figure Lengend Snippet: Segmentation illustration of tumor T1WI and CE-T1WI sequence imaging. Patient a is a 66-year-old male with unmethylated MGMT status, and patient b is a 68-year-old female with methylated MGMT status. The red region represents the NCR, the yellow region represents the ET, and the green region represents the PED

Article Snippet: The inclusion criteria included: (1) comprehensive imaging, pathological, and clinical data; (2) pathological confirmation of glioblastoma (WHO CNS 2021) with a definitive diagnosis of MGMT promoter methylation status (in house method developed by UCSF clinical labs, https://genomics.ucsf.edu/content/mgmt-promoter-methylation-assay ); (3) surgical intervention within one week following MRI examination; and (4) absence of any prior surgical, radiotherapy, or chemotherapy treatments before the MRI examination.

Techniques: Sequencing, Imaging, Methylation

Journal: Cancer Imaging

Article Title: Assessment of MGMT promoter methylation status in glioblastoma using deep learning features from multi-sequence MRI of intratumoral and peritumoral regions

doi: 10.1186/s40644-024-00817-1

Figure Lengend Snippet: Prediction results of MGMT promoter methylation status using different models

Article Snippet: The inclusion criteria included: (1) comprehensive imaging, pathological, and clinical data; (2) pathological confirmation of glioblastoma (WHO CNS 2021) with a definitive diagnosis of MGMT promoter methylation status (in house method developed by UCSF clinical labs, https://genomics.ucsf.edu/content/mgmt-promoter-methylation-assay ); (3) surgical intervention within one week following MRI examination; and (4) absence of any prior surgical, radiotherapy, or chemotherapy treatments before the MRI examination.

Techniques: Methylation

Journal: Genes

Article Title: Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma

doi: 10.3390/genes13081439

Figure Lengend Snippet: Pathological and molecular characteristics according to IDH1 G105G SNP status.

Article Snippet: Methyl-guanosine methyl transferase (MGMT) promoter methylation status has been analyzed by pyrosequencing, using a ≥9% average methylation level of CpG islands to define the methylated cases, according to Dunn J et al. [ ].

Techniques: Methylation

Journal: Genes

Article Title: Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma

doi: 10.3390/genes13081439

Figure Lengend Snippet: PFS analysis of clinical/pathological/molecular features by Cox regression.

Article Snippet: Methyl-guanosine methyl transferase (MGMT) promoter methylation status has been analyzed by pyrosequencing, using a ≥9% average methylation level of CpG islands to define the methylated cases, according to Dunn J et al. [ ].

Techniques: Methylation

Journal: Genes

Article Title: Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma

doi: 10.3390/genes13081439

Figure Lengend Snippet: DSS analysis of clinical/pathological/molecular features by Cox regression.

Article Snippet: Methyl-guanosine methyl transferase (MGMT) promoter methylation status has been analyzed by pyrosequencing, using a ≥9% average methylation level of CpG islands to define the methylated cases, according to Dunn J et al. [ ].

Techniques: Methylation

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Summary of Cohort Characteristics and Treatments

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques: Methylation, Biomarker Discovery

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Overall survival (OS) outcomes of patients stratified by MGMT promoter methylation status. (A) OS of the entire patient cohort. (B) OS of patients diagnosed with glioblastoma multiforme (GBM). (C) OS of patients diagnosed with anaplastic astrocytoma (AA) and low-grade astrocytoma (LA). (D) OS of patients diagnosed with anaplastic oligodendroglioma (AO) and low-grade oligodendroglioma (LO). (E) OS of patients diagnosed with AA. (F) OS of patients diagnosed with LA. (G) OS of patients diagnosed with AO. (H) OS of patients diagnosed with LO.

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques: Methylation

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Multivariate Analysis of OS in Various Pathological Subgroups

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques:

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Progression-free survival (PFS) outcomes of patients stratified by MGMT promoter methylation status. (A) PFS of the entire patient cohort. (B) PFS of patients diagnosed with glioblastoma multiforme (GBM). (C) PFS of patients diagnosed with anaplastic astrocytoma (AA) and low-grade astrocytoma (LA). (D) PFS of patients diagnosed with anaplastic oligodendroglioma (AO) and low-grade oligodendroglioma (LO). (E) PFS of patients diagnosed with AA. (F) PFS of patients diagnosed with LA. (G) PFS of patients diagnosed with AO. (H) PFS of patients diagnosed with LO.

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques: Methylation

Journal: Neuro-oncology Advances

Article Title: Prognostic value of O 6 -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas

doi: 10.1093/noajnl/vdac030

Figure Lengend Snippet: Multivariate Analysis of PFS in Various Pathological Subgroups

Article Snippet: The majority of MGMT gene promoter methylation assays was performed by LabCorp or NeoGenomics Laboratories using bisulfite modification of tumor deoxyribonucleic acid (DNA) and polymerase chain reaction (PCR) to detect CpG methylation.

Techniques: